anonymous
Guest
anonymous
Guest
They would weed out literally everyone, because that’s the only reason anyone is staying now. Those who can sell will go to a true buy and bill company and be allowed to sell. Those who can’t will find another pharma gig.1. It sounds like YOU may not have the ability to “sell something”
2. I have a right to call out an incentive plan that is completely out of whack. Wha wha wha, I can’t overcome objections but still pay me $100k. Maybe if they went to straight commissions they could weed out low energy sample droppers like yourself,
Nearly every process Novartis has put in place with Leqvio is a hindrance to sales. It’s way too easy for you to blame sales when you leaders have no prior experience successfully selling a buy and bill product.